# World Journal of Clinical Cases

## Contents

<table>
<thead>
<tr>
<th>Section</th>
<th>Title</th>
<th>Page</th>
</tr>
</thead>
<tbody>
<tr>
<td>REVIEW</td>
<td>Gut microbiome: New perspectives for type 2 diabetes prevention and treatment</td>
<td>7508</td>
</tr>
<tr>
<td></td>
<td>Li SX, Guo Y</td>
<td></td>
</tr>
<tr>
<td>MINIREVIEWS</td>
<td>Endoscopic management of benign biliary strictures: Looking for the best stent to place</td>
<td>7521</td>
</tr>
<tr>
<td></td>
<td>Antibiotic resistance in patients with liver cirrhosis: Prevalence and current approach to tackle</td>
<td>7530</td>
</tr>
<tr>
<td></td>
<td>Liakina V</td>
<td></td>
</tr>
<tr>
<td>ORIGINAL ARTICLE</td>
<td>Analysis of risk factors for postoperative deep vein thrombosis after craniotomy and nomogram model construction</td>
<td>7543</td>
</tr>
<tr>
<td></td>
<td>Su ZJ, Wang HR, Liu LQ, Li N, Hong XY</td>
<td></td>
</tr>
<tr>
<td></td>
<td>Value of ultrasound and magnetic resonance imaging combined with tumor markers in the diagnosis of ovarian tumors</td>
<td>7553</td>
</tr>
<tr>
<td></td>
<td>Yang Q, Zhang H, Ma PQ, Peng B, Yin GT, Zhang NN, Wang HB</td>
<td></td>
</tr>
<tr>
<td></td>
<td>Measurement of combined flap thickness for reconstruction of decubitus ulcer using computed tomography</td>
<td>7562</td>
</tr>
<tr>
<td></td>
<td>Kim EC, Park JD, Wee SY, Kim SY</td>
<td></td>
</tr>
<tr>
<td></td>
<td>Does the advantage of transcutaneous oximetry measurements in diabetic foot ulcer apply equally to free flap reconstruction?</td>
<td>7570</td>
</tr>
<tr>
<td></td>
<td>Lee DW, Hwang YS, Byeon JY, Kim BH, Choi HJ</td>
<td></td>
</tr>
<tr>
<td>Clinical Trials Study</td>
<td>Effects of ulinastatin therapy in deep vein thrombosis prevention after brain tumor surgery: A single-center randomized controlled trial</td>
<td>7583</td>
</tr>
<tr>
<td>Observational Study</td>
<td>Network pharmacological and molecular docking study of the effect of Liu-Wei-Bu-Qi capsule on lung cancer</td>
<td>7593</td>
</tr>
<tr>
<td></td>
<td>Yang Q, Li LY</td>
<td></td>
</tr>
</tbody>
</table>
Contents

Efficacy of β2-adrenergic receptor agonist combined with corticosteroid in the treatment of children with cough variant asthma
Cao JY, Wang YC, Deng XX

Randomized Controlled Trial

Protective effect of sevoflurane on lung function of elderly chronic obstructive pulmonary disease patients undergoing total hip arthroplasty
Yao Y, Zhang MS, Li YB, Zhang MZ

CASE REPORT

Sunitinib-induced hyperammonemic encephalopathy in metastatic gastrointestinal stromal tumors: A case report
Hayakawa T, Funakoshi S, Hamamoto Y, Hirata K, Kanai T

Simultaneous lateral and subxiphoid access methods for safe and accurate resection of a superior vena cava aneurysm: A case report
Kim SP, Son J

Ultrafast power Doppler imaging for ischemic encephalopathy: A case report
Huang LJ, Jiao JF, He Q, Luo JW, Guo Y

Intermittent spontaneous ovulation in patients with premature ovarian failure: Three case reports and review of literature
Zhang WY, Wang HB, Deng CY

Sneddon's syndrome concurrent with cerebral venous sinus thrombosis: A case report
Heng Y, Tang YF, Zhang XW, Duan JF, Shi J, Luo Q

Carcinosarcoma of the deep lobe of the parotid gland in the parapharyngeal region: A case report

Malignant peripheral nerve sheath tumor with hemophilic syndrome and bone marrow fibrosis: A rare case report

Comparison of drug concentrations in blood and gastric lavage fluid before and after gastric lavage: A case report
Zhou Y, Tong JL, Peng AH, Xu SY

Recurred forehead osteoma disseminated after previous osteoma excision: A case report
Lee DY, Lim S, Yoon JS, Eo S

Renal pelvis sarcomatoid carcinoma with renal vein tumor thrombus: A case report and literature review
Guan HY, Wang J, Wang JX, Chen QH, Lu J, He L

Ultrasonographic identification of lateral femoral cutaneous nerve anatomical variation in persistent meralgia paresthetica: A case report
Park HW, Ji KS, Kim JH, Kim LN, Ha KW
Contents

Thrice Monthly Volume 11 Number 31 November 6, 2023

7706  Biliary hemorrhage caused by a malignant small round cell tumor in the common bile duct: A case report
       Jin YL, Ruan YJ, Lu GR

7712  Successive development of ischemic malignant strokes in a patient with multiple fusiform aneurysms: A case report
       Shin DS, Yeo DK, Choi EJ

7718  Isolated axillary tumor deposit consistent with primary breast carcinoma: A case report
       Li T, Zhang WH, Liu J, Mao YL, Liu S

7724  Multiple inflammatory pseudotumor formation after craniopharyngioma resection via an extended nasal endoscopic approach: A case report
       Wu H, Ding YW, Yan ZC, Wei M, Wang XD, Zhang HZ

7732  Huge Bartholin’s cyst managed by primary marsupialization: A case report
       Li HY, Ding DC

LETTER TO THE EDITOR

7738  Do not forget diet and exercise during Ramadan
       Ilias I, Tselebis A
ABOUT COVER
Editorial Board Member of World Journal of Clinical Cases, How-Ran Guo, DSc, MD, MSc, Full Professor, Department of Environmental and Occupational Health, College of Medicine, National Cheng Kung University, Tainan 70428, Taiwan. hrguo@mail.ncku.edu.tw

AIMS AND SCOPE
The primary aim of World Journal of Clinical Cases (WJCC, World J Clin Cases) is to provide scholars and readers from various fields of clinical medicine with a platform to publish high-quality clinical research articles and communicate their research findings online.

WJCC mainly publishes articles reporting research results and findings obtained in the field of clinical medicine and covering a wide range of topics, including case control studies, retrospective cohort studies, retrospective studies, clinical trials studies, observational studies, prospective studies, randomized controlled trials, randomized clinical trials, systematic reviews, meta-analysis, and case reports.

INDEXING/ABSTRACTING
The WJCC is now abstracted and indexed in Science Citation Index Expanded (SCIE, also known as SciSearch®), Journal Citation Reports/Science Edition, Current Contents®/Clinical Medicine, PubMed, PubMed Central, Reference Citation Analysis, China National Knowledge Infrastructure, China Science and Technology Journal Database, and Superstar Journals Database. The 2023 Edition of Journal Citation Reports® cites the 2022 impact factor (IF) for WJCC as 1.1; IF without journal self cites: 1.1; 5-year IF: 1.3; Journal Citation Indicator: 0.26; Ranking: 133 among 167 journals in medicine, general and internal; and Quartile category: Q4.

RESPONSIBLE EDITORS FOR THIS ISSUE
Production Editor: Si Zhao; Production Department Director: Xiang Li; Editorial Office Director: Jin-Lei Wang.

NAME OF JOURNAL
World Journal of Clinical Cases

ISSN
ISSN 2307-8960 (online)

LAUNCH DATE
April 16, 2013

FREQUENCY
Thrice Monthly

EDITORS-IN-CHIEF
Bao-Gan Peng, Salim Surani, Jerzy Tadeusz Chudek, George Kontogeorgos, Maurizio Serati

EDITORIAL BOARD MEMBERS
https://www.wjgnet.com/2307-8960/editorialboard.htm

PUBLICATION DATE
November 6, 2023

COPYRIGHT
© 2023 Baishideng Publishing Group Inc

INSTRUCTIONS TO AUTHORS
https://www.wjgnet.com/bpg/gerinfo/204

GUIDELINES FOR ETHICS DOCUMENTS
https://www.wjgnet.com/bpg/gerinfo/287

GUIDELINES FOR NON-NATIVE SPEAKERS OF ENGLISH
https://www.wjgnet.com/bpg/gerinfo/240

PUBLICATION ETHICS
https://www.wjgnet.com/bpg/gerinfo/288

PUBLICATION MISCONDUCT
https://www.wjgnet.com/bpg/gerinfo/208

ARTICLE PROCESSING CHARGE
https://www.wjgnet.com/bpg/gerinfo/242

STEPS FOR SUBMITTING MANUSCRIPTS
https://www.wjgnet.com/bpg/gerinfo/239

ONLINE SUBMISSION
https://www.f6publishing.com
Efficacy of β2-adrenergic receptor agonist combined with corticosteroid in the treatment of children with cough variant asthma

Jun-Yi Cao, Ying-Chun Wang, Xiao-Xia Deng

BACKGROUND
Cough variant asthma (CVA) is one of the most common respiratory diseases in children, which has a serious impact on the quality of life and daily activities of children. For severe CVA, immunomodulatory drugs are needed.

AIM
To evaluate the efficacy of salmeterol combined with budesonide in the treatment of pediatric CVA.

METHODS
130 children with CVA from January 2020 to December 2022 were prospectively selected and randomly divided into an observation group (salmeterol combined with budesonide) and a control group (budesonide combined with a placebo). Compare the clinical efficacy of two groups before and after intervention. The evaluation parameters include cough frequency score, nocturnal cough arousal, and lung function indicators. Serum inflammatory markers, immune function markers and airway anatomical indicators were also measured.

RESULTS
After the intervention, the total effective rate of the observation group was significantly higher than that of the control group, and the cough frequency score and the night cough wake rate of the observation group were lower than that of the control group, with a statistically significant difference. In addition, the changes of lung function indicators, serum markers and immune function markers in the observation group were better than those in the control group.
CONCLUSION
The clinical efficacy of salmeterol combined with budesonide in the treatment of CVA is better than that of budesonide alone.

Key Words: Salmeterol; Budesonide; Cough variant asthma; Pediatrics; Efficacy analysis

©The Author(s) 2023. Published by Baishideng Publishing Group Inc. All rights reserved.

Core Tip: Cough variant asthma (CVA) seriously affects children's daily activities and physical health. For severe CVA, immunomodulatory drugs are needed. The purpose of this study is to evaluate the efficacy of salmeterol combined with budesonide in the treatment of CVA in children. The results showed that after the intervention, the clinical symptoms of patients in the observation group were lighter and the level of immune markers was higher. The results of this study show that the combined treatment of the two drugs is better than budesonide alone.

INTRODUCTION
Cough variant asthma (CVA) is one of the most common airway diseases in children and is characterized by cough as the main symptom while other typical asthma symptoms may not be obvious[1,2]. The prevalence of CVA in children is increasing year by year, which has a serious impact on the quality of life and daily activities of children[3-4]. Currently, drugs used to treat CVA include inhaled corticosteroids (ICS), bronchodilators, leukotriene receptor antagonists, long-acting anticholinergics, and immunomodulators[5-9]. ICS drugs such as beclometasone propionate, fluticasone and budesonide are used to relieve coughs and asthma attacks by reducing airway inflammation and controlling symptoms. Bronchodilators relieve airway spasms and dilate the airway by relaxing the smooth muscle of the airway to relieve coughing and breathing difficulties, and the main bronchodilators include short-acting β2-agonists such as salbutamol and long-acting β2 receptor agonist (LABA) such as salmeterol. Leukotriene receptor antagonists block leukotriene receptors, reduce airway inflammation and relieve asthma symptoms. Long-acting anticholinergic drugs relieve airway spasm and improve lung function by blocking cholinergic receptors. For severe CVA, immunomodulatory drugs may need to be considered to regulate the immune system's overresponse and reduce airway inflammation[10,11].

As a common medical treatment, ICS are commonly used in the treatment of asthma to reduce airway inflammation and control symptoms[12,13]. However, some ICS have limited efficacy in children with CVA and may need to be combined with other medications to achieve better control[14]. In recent studies, ICS in combination with LABA such as salmeterol can provide a more effective treatment strategy[15,16]. Salmeterol acts as a LABA to relieve airway spasms by dilating airway smooth muscle[17]. Budesonide is a potent ICS that reduces airway inflammation and controls asthma symptoms[18]. However, comprehensive studies and evaluations on the efficacy of salmeterol combined with budesonide in children with cough-variant asthma are lacking. The aim of this study was to systematically evaluate the efficacy of the salmeterol, a LABA, combined with budesonide, an ICS, in the treatment of children with CVA, and to explore its effect on clinical efficacy and recovery indicators of childhood asthma control.

MATERIALS AND METHODS
Participants
This study used a prospective approach to select 130 children with CVA who were diagnosed and treated at our hospital between January 2020 and December 2022. The patients were randomly assigned (1:1) to observation group and control group using random number table method. The observation group received salmeterol combined with budesonide, while the control group received the budesonide combined with placebo. The baseline characteristics were balanced between the 2 groups. The comparison of basic data between the two groups before intervention showed that the difference was not statistically significant and was comparable (Table 1). This study protocol was approved by the Ethics Committee of the first People's Hospital of Jiangxia District, Wuhan, and all the children's families have voluntarily participated in the study and have signed informed consent forms.

Inclusion and exclusion criteria
All the children met the diagnostic criteria of pediatric CVA[1]. The main eligibility criteria included: (1) Cough: Persistent or periodic cough, lasting at least 4 wk, and frequent attacks; (2) Variability: Cough changes significantly in
response to different triggers, such as exercise, cold air, viral infection, or allergies; (3) Wheezing sounds: Wheezing sounds can be heard during an asthma attack or when airflow is blocked; (4) Doctors make a comprehensive assessment based on the child’s medical history, symptoms and signs; and (5) Voluntarily participate in this study and cooperate with relevant examinations.

The main exclusion criteria were: (1) Complicated with serious heart, liver, kidney and other dysfunction; (2) Persistent cough caused by other causes, such as respiratory infections, chronic bronchitis, etc.; (3) Chronic cough induced by mycoplasma infection; (4) Half-treatment withdrawal or late follow-up lost contact; and (5) Allergic to the drug in this study.

**Therapeutic method**

On the basis of conventional treatment, children in the observation group were treated with Budesonide (Shanghai Xinyi Pharmaceutical Co., LTD., China, SFDA Approval No. H20010552) combined with Salmeterol aerosol (Glaxo Wellcome Production, French, Registration No. H20140382) for atomization inhalation. And the children in the control group were treated with atomized inhalation of Budesonide combined placebo. In the course of atomizing inhalation therapy, In the course of treatment, both drugs are used 1 press at a time, the oxygen flow rate is 6-8 L/min and the treatment is performed twice a day for 2 mo. During the treatment period, all children received anti-asthmatic, anti-infection and other conventional symptomatic treatment.

**Observe indicators**

Clinical efficacy: According to the Clinical practice guidelines for the diagnosis and management of children with cough in China (version 2021) diagnostic criteria[19], the clinical efficacy of the two groups was evaluated, including the following aspects: (1) The number of daytime symptoms; (2) The number of emergency relievers used; (3) Number of awakenings caused by nighttime asthma symptoms; and (4) Exercise restriction due to asthma. The evaluation criteria are as follows: Obvious effect: Children’s cough, wheezing and other symptoms disappeared, and lung function was significantly improved; Effective: The clinical symptoms were relieved and the lung function was improved. Ineffective: The symptoms and signs of the child were basically unchanged. The formula for calculating the total effective rate is:

\[ \text{Total effective rate} = \frac{\text{Obvious cases} + \text{effective cases}}{\text{total number of cases}} \times 100\% \]

Cough score: According to the Guidelines for the Diagnosis and Treatment of Cough (2021)[19], the cough symptoms of the two groups of children were evaluated, 0 points: No cough during the day or night; 1 point: Intermittent coughing during the day or waking up coughing once during the night.; 2 points: Cough intermittently or singly during the day or waking up coughing twice during the night; 3 points: Paroxysmal coughing during the day or waking up coughing more than three times during the night. A higher score referred to more serious cough.

Pulmonary function assay: Before and after treatment, forced vital capacity (FVC), forced expiratory volume in one second (FEV1), peak expiratory flow (PEF) and maximal voluntary ventilation (MVV) of the two groups were measured by a pulmonary function tester (Zhejiang Yiliankang Medical Equipment Co., LTD, China, size: PF286), and the ratio of FEV1 to FVC was calculated.

Immunofunction assay: Before and after treatment, 5 mL fasting blood samples were taken from the peripheral veins of all patients. Serum was obtained from the samples after centrifugation, and CD4\(^+\), CD8\(^+\) and CD14\(^+\) cells were analyzed during the detection by flow cytometry of CytoFocus421 of Beijing Zhizhen Biotechnology Co., LTD.

Immunglobulin assay: The blood samples were centrifuged by an automatic centrifuge (Microfuge 20/20R) with a centrifuge parameter set at 3000 RPM, a centrifuge radius of 10 cm, and a centrifuge time of 15 min. After centrifugation, the supernatant is taken and stored at -80 \(^{\circ}\)C. Subsequently, serum expression concentrations of immunoglobulin A (IgA) and immunoglobulin M (IgM) were measured using the Beckman Coulter AU5800 biochemical analyzer. The kit used is from Shanghai Huzhen Industrial Co., LTD.

Serum inflammatory indexes were measured: The venous blood collection method was the same as described above. After the blood samples were collected, the serum interleukin-6 (IL-6), interleukin-4 (IL-4) and tumor necrosis factor-a (TNF-a) concentrations were detected by enzyme-linked immunosorbent assay.

Airway anatomical index: Lung scans were performed using GE Lightspeed spiral computed tomography (CT) and Barc displays, ranging from the autonomic arterial arch to the bottom layer of the lung. The scanned images were saved and analyzed. To ensure the accuracy of the results, two experienced radiologists took independent measurements using

<table>
<thead>
<tr>
<th>Group</th>
<th>Number of cases</th>
<th>Age (yr)</th>
<th>Man</th>
<th>Woman</th>
<th>Weight (kg)</th>
<th>Course of disease (mo)</th>
<th>Vitamin D consumption D (ng/mL)</th>
<th>Spring (n)</th>
<th>Summer (n)</th>
<th>Autumn (n)</th>
<th>Winter (n)</th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>Observation group</strong></td>
<td>65</td>
<td>7.86 ± 1.56</td>
<td>35</td>
<td>30</td>
<td>25.3 ± 3.18</td>
<td>7.6 ± 2.5</td>
<td>27.5 ± 5.87</td>
<td>15</td>
<td>8</td>
<td>14</td>
<td>28</td>
</tr>
<tr>
<td><strong>Control group</strong></td>
<td>65</td>
<td>8.36 ± 1.28</td>
<td>36</td>
<td>29</td>
<td>26.7 ± 3.89</td>
<td>6.9 ± 3.2</td>
<td>26.8 ± 6.21</td>
<td>21</td>
<td>10</td>
<td>11</td>
<td>23</td>
</tr>
</tbody>
</table>

\[ \chi^2 \] | / | 1.893 | 0.389 | 0.968 | 0.987 | 0.798 | 1.562 | 2.784 |

P value | / | 0.562 | 0.256 | 0.527 | 0.332 | 0.189 | 0.636 | 0.546 |
blind methods and averaged them. In the process of measurement, the window width of 1500 Hu and window position of -450 Hu were used to select 5 CT levels at the end of inspiratory breath of children with asthma. The image was enlarged on the display and lumen diameters were measured on segmental, subsegmental bronchus and transsectional images. At the same time, the outer diameter and inner diameter of the airway cavity were measured. Finally, the airway wall thickness and airway wall area are calculated automatically by a calculation program.

**Statistical analysis**

SPSS 20.0 statistical software was used to analyze the data. The counting data were expressed as [example (%)], and 2 test or Fisher exact probability method. The measurement data conforming to the normal distribution were expressed as (mean ± SD), and the comparison between the two groups was performed by t-test, and $P < 0.05$ was considered statistically significant.

**RESULTS**

**Clinical data**

Basic data of children in observation group and control group were collected, including age, sex, weight, course of disease, vitamin D consumption and season of onset. The observation group consisted of 35 males and 30 females. The average age of the patients was (7.86 ± 1.56) years, and the average course of disease was (7.6 ± 2.5) mo. In the control group, there were 36 males and 29 females. The average age of the patients was (8.36 ± 1.28) years, and the average course of disease was (6.9 ± 3.2) mo. There was no significant difference in the general data between the two groups ($P > 0.05$) (Table 1).

**Comparison of clinical efficacy**

The total effective efficacy rate in the observation group (96.92%) was higher than the control group (90.77%), with statistical difference ($P < 0.05$), as shown in Table 2. Indicating that the efficacy of Salmeterol combined with Budesonide in the treatment of children with CVA was higher than that of Budesonide alone.

**Comparison of clinical cough score**

After treatment, the score of cough frequency and the number of cough wake times in the two groups were decreased, and the difference was statistically significant ($P < 0.05$). At the same time, the reduction rate of salmeterol combined with budesonide was significantly higher than that of budesonide alone ($P < 0.05$) (Table 3).

**Comparison of pulmonary function**

The post-treatment MVV, PEF, FEV1 and FEV1/FVC were higher than those pretreatment in both groups ($P < 0.05$). Moreover, the post-treatment MVV, PEF, FEV1 and FEV1/FVC in the observation group were higher than those in the control group ($P < 0.05$) (Table 4). The results showed that salmeterol combined with budesonide improved lung function better than budesonide alone.

**Comparison of inflammatory response**

The serum levels of IL-4, IL-6 and TNF-α were compared between the two groups before and after treatment, and there was no statistical difference between the observation group and the control group before treatment ($P > 0.05$). The post-treatment IL-6, IL-4 and TNF-α levels were lower than those pre-treatment in both groups ($P < 0.05$), and post-treatment IL-6, IL-4 and TNF-α levels in the observation group were lower than those in the control group ($P < 0.05$) (Table 5). These results indicated that salmeterol combined with Budesonide was more effective in improving inflammatory response than Budesonide alone.

**Comparison of T lymphocyte count**

Before treatment, the levels of CD4$, CD8$ and CD4$ cells count between the observation group and the control group has no statistical difference ($P > 0.05$). After treatment, the CD4$ and CD8$ cells count in both groups were higher than before treatment ($P < 0.05$), while the CD4$ cells count were lower than before treatment ($P < 0.05$). Also, the post-treatment CD4$ and CD8$ cells count in observation group was higher, while CD4$ cells count was lower in the observation group than those in the control group ($P < 0.05$) (Table 6).

**Comparison of immunoglobulin degree**

The post-treatment serum IgA and IgM levels were higher than those before treatment in both groups ($P < 0.05$), and the post-treatment levels in the observation group were higher than those in the control group ($P < 0.05$) (Table 7).

**Comparison of airway anatomical index**

Airway wall thickness and total airway wall area were compared between the two groups before and after treatment, and there was no significant difference between the two group before treatment ($P > 0.05$). After treatment, airway wall thickness and total area decreased in both groups ($P < 0.05$), and the above parameters in the observation group were lower than those in the control group ($P < 0.05$) (Table 8).
**Table 2 Comparison of efficacy between the two groups, n (%)**

<table>
<thead>
<tr>
<th>Group</th>
<th>Number of cases</th>
<th>Obvious effect</th>
<th>Effective</th>
<th>Ineffective</th>
<th>Total effective efficacy rate</th>
</tr>
</thead>
<tbody>
<tr>
<td>Control group</td>
<td>65</td>
<td>30 (46.15)</td>
<td>29 (44.62)</td>
<td>6 (9.23)</td>
<td>59 (90.77)</td>
</tr>
<tr>
<td>Control group</td>
<td>65</td>
<td>38 (58.46)</td>
<td>25 (38.46)</td>
<td>2 (3.08)</td>
<td>63 (96.92)</td>
</tr>
</tbody>
</table>

$\chi^2$ = 9.562

$P$ value = 0.001

*p < 0.05 vs control group.

**Table 3 Comparison of clinical cough score between the two groups**

<table>
<thead>
<tr>
<th>Clinical cough score</th>
<th>Pre-treatment</th>
<th>Post-treatment</th>
<th>$t$</th>
<th>$P$ value</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td>Observation group ($n = 65$)</td>
<td>Control group ($n = 65$)</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Cough score</td>
<td>2.06 ± 1.22</td>
<td>2.26 ± 1.63</td>
<td>1.067</td>
<td>0.287</td>
</tr>
<tr>
<td>Nighttime coughs</td>
<td>3.16 ± 2.01</td>
<td>3.28 ± 1.06</td>
<td>1.892</td>
<td>0.092</td>
</tr>
</tbody>
</table>

$*P < 0.05$ before treatment.

**Table 4 Comparison of pulmonary function between the two groups**

<table>
<thead>
<tr>
<th>Pulmonary function index</th>
<th>Pre-treatment</th>
<th>Post-treatment</th>
<th>$t$</th>
<th>$P$ value</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td>Observation group ($n = 65$)</td>
<td>Control group ($n = 65$)</td>
<td></td>
<td></td>
</tr>
<tr>
<td>MVV (L/min)</td>
<td>4.26 ± 0.22</td>
<td>4.32 ± 0.63</td>
<td>1.956</td>
<td>0.643</td>
</tr>
<tr>
<td>FEV1 (L)</td>
<td>1.16 ± 0.21</td>
<td>1.28 ± 0.66</td>
<td>1.537</td>
<td>0.291</td>
</tr>
<tr>
<td>FEV1/FVC (%)</td>
<td>64.6 ± 5.34</td>
<td>65.4 ± 4.65</td>
<td>0.958</td>
<td>0.452</td>
</tr>
<tr>
<td>PEF (L/s)</td>
<td>2.23 ± 0.56</td>
<td>2.08 ± 0.58</td>
<td>1.071</td>
<td>0.749</td>
</tr>
</tbody>
</table>

$*P < 0.05$ before and after intervention in the same group.

MVV: Maximal voluntary ventilation; FEV1: Forced expiratory volume in one second; FVC: Forced vital capacity; PEF: Peak expiratory flow.

**Table 5 Comparison of inflammatory response between the two groups before and after treatment (mean ± SD)**

<table>
<thead>
<tr>
<th>Inflammatory response index</th>
<th>Pre-treatment</th>
<th>Post-treatment</th>
<th>$t$</th>
<th>$P$ value</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td>Observation group ($n = 65$)</td>
<td>Control group ($n = 65$)</td>
<td></td>
<td></td>
</tr>
<tr>
<td>IL-6 (ng/L)</td>
<td>25.78 ± 5.18</td>
<td>25.32 ± 4.63</td>
<td>2.132</td>
<td>0.097</td>
</tr>
<tr>
<td>IL-4 (ng/L)</td>
<td>24.6 ± 4.34</td>
<td>23.4 ± 3.65</td>
<td>1.267</td>
<td>0.258</td>
</tr>
<tr>
<td>TNF-α (pg/L)</td>
<td>1.27 ± 0.32</td>
<td>1.28 ± 0.63</td>
<td>1.879</td>
<td>0.784</td>
</tr>
</tbody>
</table>

$^bP < 0.05$ vs compare before and after intervention in the same group.

IL-6: Interleukin-6; IL-4: Interleukin-4; TNF-α: Tumor necrosis factor-α.

**DISCUSSION**

CVA is a common type of childhood asthma characterized by a chronic cough with symptoms that fluctuate wildly across time and environment[6]. Salmeterol, a long-acting beta-2 adrenergic receptor agonist, is a commonly used asthma medication that reduces airway spasms by dilating bronchial smooth muscles, thereby relieving breathing difficulties and
### Table 6 Comparison of T-lymphocytes count between the two groups before and after treatment (mean ± SD)

<table>
<thead>
<tr>
<th>Group</th>
<th>Pre-treatment CD(^{3+} ) (%)</th>
<th>Post-treatment CD(^{3+} ) (%)</th>
<th>( t )</th>
<th>( P ) value</th>
<th>Pre-treatment CD(^{4+} ) (%)</th>
<th>Post-treatment CD(^{4+} ) (%)</th>
<th>( t )</th>
<th>( P ) value</th>
<th>Pre-treatment CD(^{8+} ) (%)</th>
<th>Post-treatment CD(^{8+} ) (%)</th>
<th>( t )</th>
<th>( P ) value</th>
</tr>
</thead>
<tbody>
<tr>
<td>Observation group (n = 65)</td>
<td>44.6 ± 6.34</td>
<td>67.4 ± 4.65</td>
<td>-8.25</td>
<td>0.008</td>
<td>29.8 ± 5.56</td>
<td>42.8 ± 5.06</td>
<td>-9.78</td>
<td>0.011</td>
<td>33.2 ± 5.21</td>
<td>25.6 ± 4.89</td>
<td>10.6</td>
<td>0.012</td>
</tr>
<tr>
<td>Control group (n = 65)</td>
<td>44.7 ± 7.32</td>
<td>58.8 ± 5.63</td>
<td>-2.67</td>
<td>0.004</td>
<td>28.3 ± 5.25</td>
<td>38.9 ± 7.48</td>
<td>-8.96</td>
<td>0.012</td>
<td>32.7 ± 6.18</td>
<td>28.5 ± 5.12</td>
<td>9.78</td>
<td>0.023</td>
</tr>
<tr>
<td>( t )</td>
<td>1.785</td>
<td>2.165</td>
<td>0.895</td>
<td>2.418</td>
<td>0.794</td>
<td>0.947</td>
<td>0.001</td>
<td>0.003</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>( P ) value</td>
<td>0.562</td>
<td>0.024</td>
<td>0.732</td>
<td>0.002</td>
<td>0.001</td>
<td>0.003</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
</tbody>
</table>

### Table 7 Comparison of immunoglobulin levels between the two groups before and after treatment (mean ± SD)

<table>
<thead>
<tr>
<th>Group</th>
<th>Pre-treatment IgA (g/L)</th>
<th>Post-treatment IgA (g/L)</th>
<th>( t )</th>
<th>( P ) value</th>
<th>Pre-treatment IgM (g/L)</th>
<th>Post-treatment IgM (g/L)</th>
<th>( t )</th>
<th>( P ) value</th>
</tr>
</thead>
<tbody>
<tr>
<td>Observation group (n = 65)</td>
<td>1.26 ± 0.34</td>
<td>1.84 ± 0.65</td>
<td>-7.23</td>
<td>0.012</td>
<td>9.08 ± 1.56</td>
<td>11.8 ± 1.06</td>
<td>-6.98</td>
<td>0.021</td>
</tr>
<tr>
<td>Control group (n = 65)</td>
<td>1.27 ± 0.32</td>
<td>1.48 ± 0.63</td>
<td>-9.67</td>
<td>0.007</td>
<td>9.03 ± 1.25</td>
<td>10.9 ± 1.48</td>
<td>-9.56</td>
<td>0.032</td>
</tr>
<tr>
<td>( t )</td>
<td>0.765</td>
<td>6.165</td>
<td>0.655</td>
<td>2.418</td>
<td>0.751</td>
<td>0.012</td>
<td></td>
<td></td>
</tr>
<tr>
<td>( P ) value</td>
<td>0.724</td>
<td>0.014</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
</tbody>
</table>

IgA: Immunoglobulin A; IgM: Immunoglobulin M.

### Table 8 Comparison of airway anatomical index between the two groups before and after treatment (mean ± SD)

<table>
<thead>
<tr>
<th>Group</th>
<th>Pre-treatment Airway wall thickness (mm(^2))</th>
<th>Post-treatment Airway wall thickness (mm(^2))</th>
<th>( t )</th>
<th>( P ) value</th>
<th>Pre-treatment Total airway area (mm(^2))</th>
<th>Post-treatment Total airway area (mm(^2))</th>
<th>( t )</th>
<th>( P ) value</th>
</tr>
</thead>
<tbody>
<tr>
<td>Observation group (n = 65)</td>
<td>2.16 ± 0.46</td>
<td>0.84 ± 0.65</td>
<td>8.26</td>
<td>0.014</td>
<td>7.08 ± 0.56</td>
<td>3.28 ± 1.26</td>
<td>10.98</td>
<td>0.011</td>
</tr>
<tr>
<td>Control group (n = 65)</td>
<td>2.27 ± 0.22</td>
<td>1.98 ± 0.43</td>
<td>7.64</td>
<td>0.005</td>
<td>7.03 ± 0.25</td>
<td>4.39 ± 1.68</td>
<td>11.56</td>
<td>0.006</td>
</tr>
<tr>
<td>( t )</td>
<td>1.762</td>
<td>8.135</td>
<td>0.398</td>
<td>4.468</td>
<td>0.216</td>
<td>0.016</td>
<td></td>
<td></td>
</tr>
<tr>
<td>( P ) value</td>
<td>0.425</td>
<td>0.016</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
</tbody>
</table>

coughing symptoms[20]. The use of salmeterol has been widely discussed in children with CVA. Studies have shown that salmeterol is effective in reducing cough frequency and duration and improving respiratory symptoms in children. On the other hand, the corticosteroid budesonide is widely used as an anti-inflammatory drug in the treatment of asthma [21]. It can inhibit airway inflammation, reduce airway edema and excessive mucus, and thus improve airway patency. The use of budesonide has also been extensively studied in children with cough-variant asthma. Studies have shown that budesonide can significantly improve lung function and reduce inflammatory response in children[22,23]. In addition, budesonide improves immune function by increasing CD\(^{4+} \) cell count and immunoglobulin levels[18].

In this study, we observed the efficacy of the \( \beta \)2-receptor agonist salmeterol in combination with the corticosteroid budesonide in the treatment of children with cough-variant asthma. In terms of clinical efficacy, we found that the combination regimen significantly reduced cough frequency and duration, improved the overall response rate of treatment, and improved the life quality of children. In terms of lung function, the children's PEF and FEV1 were significantly improved. In addition, the serum inflammatory indicators IL-6, TNF-a, IL-4 were significantly reduced, and the improvement of immune function included the increase of the number of CD\(^{4+} \), CD\(^{3+} \) cells and the levels of immunoglobulin IgA and IgM.
CONCLUSION

In summary, the β2-receptor agonist salmeterol combined with the corticosteroid budesonide is an effective regimen for the treatment of children with cough-variant asthma. The combination therapy can significantly improve clinical symptoms, increase lung function, reduce inflammation levels, and improve immune function.

These findings have important clinical implications for clinicians in the treatment of children with cough-variant asthma, but this study has some limitations, such as a small sample size and a short study period. Therefore, future studies can further expand the sample size and extend the observation time to further validate our findings.

ARTICLE HIGHLIGHTS

Research background
The combination of inhaled corticosteroids (ICS) and long-acting β2 receptor agonist (LABA), such as salmeterol, can provide a more effective treatment strategy, but there is a lack of comprehensive research and evaluation on the efficacy of salmeterol combined with budesonide in the treatment of cough variant asthma (CVA) in children.

Research motivation
To systematically explore the efficacy of LABA salmeterol combined with ICS budesonide in the treatment of CVA in children, and to provide some clinical treatment suggestions for the treatment and clinical recovery of CVA in children.

Research objectives
The purpose of this study is to systematically evaluate the efficacy of LABA salmeterol combined with ICS budesonide in the treatment of CVA in children, and to explore the influence of the combination of the two drugs on the clinical efficacy and recovery index of asthma control in children.

Research methods
Children with CVA were selected prospectively and randomly divided into observation group (salmeterol combined with budesonide) and control group (budesonide combined with placebo). The clinical efficacy and immune function markers of the two groups were compared.

Research results
After treatment, the effect and efficiency of the two groups were improved to some extent. The symptoms of CVA in the treatment group were relieved, and the lung function index and immune marker level were also better than those in the control group.

Research conclusions
Both salmeterol combined with budesonide and budesonide alone can treat CVA to a certain extent, but the therapeutic effect of the former is significantly higher than that of the latter in symptom improvement, immune marker level and lung function level.

Research perspectives
Salmeterol combined with budesonide is an effective method to treat CVA disease, which is worth popularizing in clinic.

ACKNOWLEDGEMENTS

We are grateful to all patients for their participation.

FOOTNOTES

Co-first authors: Jun-Yi Cao and Ying-Chun Wang.

Author contributions: Cao JY, and Wang YC designed the research; Deng XX performed the research; Deng XX contributed new reagents/analytic tools; Cao JY, Wang YC, and Deng XX analyzed the data; Cao JY, and Wang YC wrote the paper. Cao JY and Ying-Chun Wang contributed equally to this work as co-first authors equally to this work. The reasons for designating Cao JY and Wang YC as co-first authors are threefold. First, the research was performed as a collaborative effort, and the designation of co-first authors authorship accurately reflects the distribution of responsibilities and burdens associated with the time and effort required to complete the study and the resultant paper. This also ensures effective communication and management of post-submission matters, ultimately enhancing the paper's quality and reliability. Second, the overall research team encompassed authors with a variety of expertise and skills from different fields, and the designation of co-first authors best reflects this diversity. This also promotes the most comprehensive and in-depth examination of the research topic, ultimately enriching readers' understanding by offering various expert perspectives. Third, Cao JY and Wang YC contributed efforts of equal substance throughout the research process. The choice of these researchers as
co-first authors acknowledges and respects this equal contribution, while recognizing the spirit of teamwork and collaboration of this study. In summary, we believe that designating Cao JY and Wang YC as co-first authors of this manuscript as it accurately reflects our team’s collaborative spirit, equal contributions, and diversity.

**Institutional review board statement:** The study was reviewed and approved by the first People's Hospital of Jiangxia District.

**Informed consent statement:** All study participants, or their legal guardian, provided informed written consent prior to study enrollment.

**Conflict-of-interest statement:** There are no conflicts of interest to report.

**Data sharing statement:** No additional data are available.

**STROBE statement:** The authors have read the STROBE Statement-checklist of items, and the manuscript was prepared and revised according to the STROBE Statement-checklist of items.

**Open-Access:** This article is an open-access article that was selected by an in-house editor and fully peer-reviewed by external reviewers. It is distributed in accordance with the Creative Commons Attribution NonCommercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. See: https://creativecommons.org/Licenses/by-nc/4.0/

**Country/Territory of origin:** China

**ORCID number:** Xiao-Xia Deng 0000-0002-2875-0730.

**S-Editor:** Qu XL

**L-Editor:** A

**P-Editor:** Zhao S

**REFERENCES**


Subspecialty Group of Pharmacology, the Society of Pediatrics; Chinese Medical Association; National Clinical Research Center for Child Health and Disorders; Subspecialty Group of Respiratory Diseases, the Society of Pediatrics, Chinese Medical Association; Children's Respiratory Professional Committee, the Society of Pediatrics of Chinese Medical Doctor Association; Editorial Board, Chinese Journal of Pediatrics. [Clinical practice guidelines for the diagnosis and management of children with cough in China (version 2021)]. *Zhonghua Er Ke Za Zhi* 2021; 59: 720-729 [PMID: 34645211 DOI: 10.3760/cma.j.cn112140-20210513-00423]

Subspecialty Group of Pharmacology, the Society of Pediatrics; Chinese Medical Association; National Clinical Research Center for Child Health and Disorders; Subspecialty Group of Respiratory Diseases, the Society of Pediatrics, Chinese Medical Association; Children's Respiratory Professional Committee, the Society of Pediatrics of Chinese Medical Doctor Association; Editorial Board, Chinese Journal of Pediatrics. [Clinical practice guidelines for the diagnosis and management of children with cough in China (version 2021)]. *Zhonghua Er Ke Za Zhi* 2021; 59: 720-729 [PMID: 34645211 DOI: 10.3760/cma.j.cn112140-20210513-00423]

Subspecialty Group of Pharmacology, the Society of Pediatrics; Chinese Medical Association; National Clinical Research Center for Child Health and Disorders; Subspecialty Group of Respiratory Diseases, the Society of Pediatrics, Chinese Medical Association; Children's Respiratory Professional Committee, the Society of Pediatrics of Chinese Medical Doctor Association; Editorial Board, Chinese Journal of Pediatrics. [Clinical practice guidelines for the diagnosis and management of children with cough in China (version 2021)]. *Zhonghua Er Ke Za Zhi* 2021; 59: 720-729 [PMID: 34645211 DOI: 10.3760/cma.j.cn112140-20210513-00423]

Subspecialty Group of Pharmacology, the Society of Pediatrics; Chinese Medical Association; National Clinical Research Center for Child Health and Disorders; Subspecialty Group of Respiratory Diseases, the Society of Pediatrics, Chinese Medical Association; Children's Respiratory Professional Committee, the Society of Pediatrics of Chinese Medical Doctor Association; Editorial Board, Chinese Journal of Pediatrics. [Clinical practice guidelines for the diagnosis and management of children with cough in China (version 2021)]. *Zhonghua Er Ke Za Zhi* 2021; 59: 720-729 [PMID: 34645211 DOI: 10.3760/cma.j.cn112140-20210513-00423]